Cannabinoid Receptors in Dogs and Cats: Similarities to Humans & Unique Features in Pets

The endocannabinoid system (ECS) is a body-wide network that helps regulate mood, pain, appetite, inflammation, and more. Humans have it. So do our pets. Dogs and cats share the same core cannabinoid receptors—CB1 and CB2—and related pathways found in people, but there are notable species-specific differences in where these receptors appear and how cannabinoids are handled by the body.^{1, 2}

At Shop Healthy Pets, we take a gut-first, whole-system approach to wellness. Understanding the ECS helps explain why foundational support—digestion, calm routines, joint comfort—pairs well with thoughtful use of pet-formulated cannabinoids, like our CBD biscuit Tranquil Tails, under your veterinarian’s guidance.

Quick Primer: CB1, CB2, and Friends

CB1 receptors concentrate in the brain and nervous system, shaping appetite, movement, and mood; CB2 receptors are more tied to immune and inflammatory responses. Pets also express “cannabinoid-like” targets (e.g., GPR55, TRPV1), which interact with endocannabinoids and some phytocannabinoids.^{1, 2}

How Pets Are Similar to Humans

• Shared architecture: Dogs and cats have CB1/CB2 receptors and ECS enzymes much like humans, enabling parallel roles in pain modulation, stress response, and GI function.^{2, 7}
• Brain & nerve distribution: In healthy dogs, CB1 has been mapped throughout the CNS and PNS—including cortex, hippocampus, cerebellum, dorsal root ganglia, and even myelinating Schwann cells—mirroring patterns seen across mammals.¹
• Immune & joint interfaces: Canine joint tissues (synovium) express CB1, CB2, and GPR55, providing a mechanistic link between the ECS and musculoskeletal comfort.³

Where Pets Are Uniquely… Pet

• Different receptor density & sensitivity: The “map” of ECS targets varies by species and tissue. Those differences can shift how dogs and cats respond to cannabinoids compared with humans.^{1, 3}
• Skin & inflammation nuances: Dogs with atopic dermatitis show CB2 and cannabinoid-related receptor expression within inflammatory infiltrates—pointing to ECS roles in itch and skin inflammation.⁴
• Pharmacokinetics (PK): Oral CBD absorption, metabolism, and clearance in dogs are variable, and long-term safety/efficacy data are still building—dose and formulation matter.^{5, 7}
• THC is risky: Unlike CBD, THC can readily cause toxicosis in dogs and cats (disorientation, urinary incontinence, bradycardia, etc.). Pet products should be formulated to avoid intoxicating levels of THC.⁸

What This Means for Holistic Care

The ECS intersects with digestion, immunity, nerves, and joints—exactly where a gut-first routine shines. We like to stack the basics:

1. Stabilize the gut terrain: A calm GI tract supports balanced ECS signaling. Consider daily ImmunoGut (probiotics + beef bone broth) and Perfect Pumpkin (soluble fiber) to nourish the microbiome and gut lining.
2. Comfort the system: Beef Bone Broth provides collagen-rich amino acids (e.g., glycine) that support mucosal integrity and recovery routines.
3. Layer calm, thoughtfully: For predictable stressors (travel, guests, vet visits), consider Tranquil Tails (CBD biscuit) and monitor behavior and sleep. Start low, go slow, and coordinate with your vet—especially if your pet takes other meds.

What Does the Research Say So Far?

• Mapping the receptors: Detailed canine CB1 mapping confirms wide CNS/PNS distribution, including Schwann cells—evidence of deep neuro-immune involvement.¹
• Pain & inflammation: Reviews in veterinary science support cannabinoids (esp. CBD-rich products) as part of multimodal pain strategies, while emphasizing quality control and dosing.^{2, 6}
• Stress physiology: A controlled study reported a single CBD dose reduced physiologic and behavioral stress measures in dogs during separation and car travel.⁹
• PK & safety landscape: Systematic reviews summarize variable oral bioavailability and generally good short-term tolerability of CBD in dogs, with more data needed for cats and long-term use.^{5, 7, 10}

References

1. Freundt-Revilla J, et al. Spatial distribution of cannabinoid receptor type 1 (CB1) in normal canine central and peripheral nervous system (2017). PLoS ONE. Open access
2. Miranda-Cortés A, et al. The role of cannabinoids in pain modulation in companion animals (2023). Front Vet Sci. Full text
3. Cunha RZ, et al. Endocannabinoid System Receptors at the Hip and Stifle Joints of Middle-Aged Dogs (2023). Animals. Open access
4. Chiocchetti R, et al. Cannabinoid receptors in the inflammatory cells of canine atopic dermatitis (2022). Front Vet Sci. Open access
5. Di Salvo A, et al. Pharmacokinetics, efficacy, and safety of cannabidiol in dogs (2023). Front Vet Sci. Open access
6. Klatzkow S, et al. CBD/CBDA-rich hemp product for post-operative pain after TPLO in dogs (2023). Front Vet Sci. Full text
7. Di Salvo A, et al. Endocannabinoid system and phytocannabinoids in veterinary species (2024). Vet Res Commun. Publisher
8. Rideout H, et al. CBD for pets: quality, safety & regulation (2025). Can J Comp Med. Open access
9. Hunt ABG, et al. A single dose of CBD positively influences stress measures in dogs (2023). Front Vet Sci. Open access
10. Di Salvo A, et al. Pharmacokinetics, efficacy, and safety of CBD in dogs (2023). Front Vet Sci. Full text

Disclaimer: Educational content only, not a substitute for individualized veterinary care. Discuss cannabinoids with your veterinarian—especially if your pet has a medical condition or takes other medications.